Outlook Therapeutics Gestione

Criteri Gestione verificati 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bob Jahr

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO	8.61%
Mandato del CEO	1yr
Proprietà del CEO	n/a
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	7.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Jun 06

Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity

Summary Outlook Therapeutics receives a buy rating due to a recent FDA appeal victory, improving the probability of US approval for Lytenava. OTLK's near-term upside is driven by regulatory catalysts, despite ongoing concerns about commercial viability and a precarious financial position. Insider buying and a key shareholder's participation in recent offerings signal confidence ahead of binary FDA and Nasdaq compliance catalysts. Valuation is highly sensitive to Lytenava's US adoption rate, with a speculative fair value range of $0.90–$1.64 per share. Read the full article on Seeking Alpha

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bob Jahr rispetto agli utili di Outlook Therapeutics?
Data	Compenso totale	Stipendio	Utili della società
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$103m
Sep 30 2025	US$2m	US$150k	-US$62m

Compensazione vs Mercato: La retribuzione totale di Bob ($USD 1.74M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.63M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Bob con le performance aziendali.

AMMINISTRATORE DELEGATO

Bob Jahr (53 yo)

1yr

Mandato

US$1,741,757

Compensazione

Mr. Robert Charles Jahr, also known as Bob, is President, Chief Executive Officer & Director of Outlook Therapeutics, Inc. from July 1, 2025. From September 2018 to April 2020, he served as Vice President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Jahr	President	1yr	US$1.74m	Nessun dato
Lawrence Kenyon	EVP, CFO	10.8yrs	US$476.17k	0.0049% $ 8.3k
Joel Prieve	Senior Vice President of Licensing and M&A	4.4yrs	Nessun dato	Nessun dato
Surendra Sharma	Senior Vice President of Medical Affairs	3.5yrs	Nessun dato	Nessun dato
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	Nessun dato	Nessun dato
Jedd Comiskey	Senior VP - Head of Europe	2.7yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

Gestione esperta: Il team dirigenziale di OTLK è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Jahr	President	1yr	US$1.74m	Nessun dato
Lawrence Kenyon	EVP, CFO	7.9yrs	US$476.17k	0.0049% $ 8.3k
Kurt Hilzinger	Independent Director	10.6yrs	US$842.00k	0.35% $ 588.9k
Ralph Thurman	Lead Independent Director	8.3yrs	US$836.50k	0.0046% $ 7.8k
Julian Gangolli	Independent Non-Employee Director	6.3yrs	US$690.50k	0% $ 0
Gerd Auffarth	Independent Non-Employee Director	6.3yrs	US$458.00k	0% $ 0
Faisal Sukhtian	Independent Chairman of the Board	8.8yrs	US$1.00m	0.10% $ 174.6k
Yezan Haddadin	Independent Director	8.8yrs	US$974.00k	0.055% $ 92.0k
Andong Huang	Independent Director	6.1yrs	US$425.00k	0% $ 0

7.9yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di OTLK sono considerati esperti (durata media dell'incarico 7.9 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/20 12:35
Prezzo dell'azione a fine giornata	2026/07/17 00:00
Utili	2026/03/31
Utili annuali	2025/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Outlook Therapeutics, Inc. è coperta da 9 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics Gestione

Criteri Gestione verificati 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently bought US$177k worth of stock

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Insufficient new directors

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Recent updates

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. Regains Compliance with Minimum Bid Price Requirement

Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD

Outlook Therapeutics Receives FDA Fast-Track for Lytenava With Key Decision Expected in 60 Days

Consensus revenue estimates increase by 200%

Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity

Independent Director recently bought US$177k worth of stock

Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process For ONS-5010/LYTENAVA (Bevacizumab-Vikg) And Plans To Resubmit BLA To FDA In June 2026

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc. Announces FDA Accepts Formal Dispute Resolution Request for ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 18%

Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics Provides Update Following Type A Meeting With FDA Regarding ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Consensus revenue estimates fall by 15%

Price target decreased by 20% to US$5.38

Outlook Therapeutics, Inc. Receives Notice of Potential Delisting Due to Low Stock Price on Nasdaq

New major risk - Revenue size

Outlook Therapeutics, Inc. Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Price target decreased by 20% to US$5.38

Price target decreased by 13% to US$5.88

New major risk - Share price stability

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

Consensus revenue estimates decrease by 53%, EPS upgraded

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010

Price target decreased by 42% to US$5.00

Insufficient new directors

Price target decreased by 10% to US$8.25

New minor risk - Profitability

Outlook Therapeutics, Inc. Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™? (Bevacizumab-Vikg) for the Treatment of Wet Amd

Consensus revenue estimates increase by 33%, EPS downgraded

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 16%

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc.(NasdaqCM:OTLK) dropped from Russell 2000 Index

Outlook Therapeutics®? Announces Smc Recommendation of Lytenava™ (Bevacizumab Grapa) for the Treatment of Wet Amd

Price target decreased by 8.8% to US$8.67

Investor sentiment improves as stock rises 17%

Outlook Therapeutics, Inc. Announces Commercial Launch of LYTENAVA (bevacizumab G gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $13 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Consensus EPS estimates fall by 32%

Price target increased by 12% to US$11.20

New major risk - Financial position

New minor risk - Share price stability

Outlook Therapeutics, Inc. Announces U.S. Food and Drug Administration Resubmission of ONS-5010 Biologics License Application

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Consensus estimates of losses per share improve by 27%

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Outlook Therapeutics, Inc. Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Price target decreased by 17% to US$16.33

Consensus revenue estimates increase by 39%

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

New major risk - Share price stability

Price target decreased by 9.5% to US$33.60